Regeneron Tarrytown Campus, Eastview, Town of Greenburgh, Westchester County, New York, United States
Regeneron Pharmaceuticals
CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Regeneron's[4] release (published by HearingTracker[1], 'Published on Apr 23, 2026') says the FDA 'has granted accelerated approval for Otarmeni'; MedCity News[3], dated April 23, 2026, calls it 'The FDA decision announced Thursday'.On 23 April 2026 the FDA granted accelerated approval to Regeneron's Otarmeni (lunsotogene parvec-cwha, formerly DB-OTO), the first gene therapy for OTOF-related hearing loss, which Regeneron will supply free of charge in the US.